| pubmed-article:20562063 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20562063 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
| pubmed-article:20562063 | lifeskim:mentions | umls-concept:C0013203 | lld:lifeskim |
| pubmed-article:20562063 | lifeskim:mentions | umls-concept:C1521797 | lld:lifeskim |
| pubmed-article:20562063 | lifeskim:mentions | umls-concept:C0085973 | lld:lifeskim |
| pubmed-article:20562063 | lifeskim:mentions | umls-concept:C0007320 | lld:lifeskim |
| pubmed-article:20562063 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:20562063 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:20562063 | pubmed:dateCreated | 2010-6-21 | lld:pubmed |
| pubmed-article:20562063 | pubmed:abstractText | The success of first-line antiretroviral therapy can be challenged by the acquisition of primary drug resistance. Here we report a case where baseline genotypic resistance testing detected resistance conferring nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)-associated mutations, but no primary mutations for protease inhibitor (PI). Subsequent PI-based HAART with boosted saquinavir led to virological treatment success with persistently undetectable viral load. After treatment simplification from saquinavir to an atazanavir based PI-therapy and no change in backbone therapy rapid virological breakthrough occurred. Retrospective analysis displayed preexisting gag cleavage site mutations which may have reduced the genetic barrier in a clinical relevant manner in combination with the already existing NRTI resistance mutations. Alternatively, this effect could be explained with a different antiviral potency for the respective PIs used. | lld:pubmed |
| pubmed-article:20562063 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20562063 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20562063 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20562063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20562063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20562063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20562063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20562063 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20562063 | pubmed:month | May | lld:pubmed |
| pubmed-article:20562063 | pubmed:issn | 0949-2321 | lld:pubmed |
| pubmed-article:20562063 | pubmed:author | pubmed-author:KaiserRR | lld:pubmed |
| pubmed-article:20562063 | pubmed:author | pubmed-author:KupferBB | lld:pubmed |
| pubmed-article:20562063 | pubmed:author | pubmed-author:RockstrohJ... | lld:pubmed |
| pubmed-article:20562063 | pubmed:author | pubmed-author:AnadolEE | lld:pubmed |
| pubmed-article:20562063 | pubmed:author | pubmed-author:VerheyenJJ | lld:pubmed |
| pubmed-article:20562063 | pubmed:author | pubmed-author:WasmuthJ CJC | lld:pubmed |
| pubmed-article:20562063 | pubmed:author | pubmed-author:EmmelkampJJ | lld:pubmed |
| pubmed-article:20562063 | pubmed:author | pubmed-author:SchülterEE | lld:pubmed |
| pubmed-article:20562063 | pubmed:author | pubmed-author:Schwarze-Zand... | lld:pubmed |
| pubmed-article:20562063 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:20562063 | pubmed:day | 18 | lld:pubmed |
| pubmed-article:20562063 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:20562063 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20562063 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20562063 | pubmed:pagination | 225-30 | lld:pubmed |
| pubmed-article:20562063 | pubmed:meshHeading | pubmed-meshheading:20562063... | lld:pubmed |
| pubmed-article:20562063 | pubmed:meshHeading | pubmed-meshheading:20562063... | lld:pubmed |
| pubmed-article:20562063 | pubmed:meshHeading | pubmed-meshheading:20562063... | lld:pubmed |
| pubmed-article:20562063 | pubmed:meshHeading | pubmed-meshheading:20562063... | lld:pubmed |
| pubmed-article:20562063 | pubmed:meshHeading | pubmed-meshheading:20562063... | lld:pubmed |
| pubmed-article:20562063 | pubmed:meshHeading | pubmed-meshheading:20562063... | lld:pubmed |
| pubmed-article:20562063 | pubmed:meshHeading | pubmed-meshheading:20562063... | lld:pubmed |
| pubmed-article:20562063 | pubmed:meshHeading | pubmed-meshheading:20562063... | lld:pubmed |
| pubmed-article:20562063 | pubmed:meshHeading | pubmed-meshheading:20562063... | lld:pubmed |
| pubmed-article:20562063 | pubmed:meshHeading | pubmed-meshheading:20562063... | lld:pubmed |
| pubmed-article:20562063 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20562063 | pubmed:articleTitle | Transmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications? | lld:pubmed |
| pubmed-article:20562063 | pubmed:affiliation | Department of General Internal Medicine, University of Bonn, Sigmund-Freud Strasse 25, 53105 Bonn, Germany. evrim.anadol@ukb.uni-bonn.de | lld:pubmed |
| pubmed-article:20562063 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20562063 | pubmed:publicationType | Case Reports | lld:pubmed |
